These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26827242)

  • 1. NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases.
    Umeweni N; Knight H; McVeigh G
    Lancet Oncol; 2016 Mar; 17(3):275-6. PubMed ID: 26827242
    [No Abstract]   [Full Text] [Related]  

  • 2. Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):3-7. PubMed ID: 27167841
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):15-6. PubMed ID: 27167846
    [No Abstract]   [Full Text] [Related]  

  • 4. Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):10-1. PubMed ID: 27167843
    [No Abstract]   [Full Text] [Related]  

  • 5. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
    Shore ND
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):26-9. PubMed ID: 27057663
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
    George DJ
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):690-694. PubMed ID: 28949940
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radium-223 dichloride in clinical practice: a review.
    Florimonte L; Dellavedova L; Maffioli LS
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical guide to the use of radium 223 dichloride.
    Den RB; Doyle LA; Knudsen KE
    Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
    Dandapani SV; Wong J; Twardowski P
    Cancer Biother Radiopharm; 2020 Sep; 35(7):490-496. PubMed ID: 32762539
    [No Abstract]   [Full Text] [Related]  

  • 12. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
    Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
    Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
    Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
    Vogelzang NJ
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
    Nilsson S
    Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
    Caffo O; Frantellizzi V; Monari F; Sbrana A; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Palermo A; Fanti S; Biasco E; Murabito A; Filice A; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; Cortesi E; Vincentis G
    Future Oncol; 2021 Mar; 17(7):807-815. PubMed ID: 33508980
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radium 223 dichloride for prostate cancer treatment.
    Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
    Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.